Author

Jean-Frédéric Colombel

EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES
EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES

Jean-Frédéric Colombel  et al.

IMPACT OF COVID-19 ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY
IMPACT OF COVID-19 ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY

Jean-Frédéric Colombel  et al.

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Jean-Frédéric Colombel  et al.

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES
A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Jean-Frédéric Colombel  et al.

MICROSCOPIC COLITIS NO MORE: HLA ASSOCIATION DISCRIMINATES COLLAGENOUS FROM LYMPHOCYTIC COLITIS
MICROSCOPIC COLITIS NO MORE: HLA ASSOCIATION DISCRIMINATES COLLAGENOUS FROM LYMPHOCYTIC COLITIS

Jean-Frédéric Colombel  et al.

Item 41 - 45 / 45
1 2
3